Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia.
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D004299:Dopamine beta-Hydroxylase / Q000097:blood*; D005476:Fluphenazine / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000201:enzymology; D013881:Thioridazine / Q000627:therapeutic use; D014268:Trifluoperazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D014268:Trifluoperazine; D004299:Dopamine beta-Hydroxylase; D006220:Haloperidol; D013881:Thioridazine; D005476:Fluphenazine; D002746:Chlorpromazine